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a  b  s  t  r  a  c  t
The  present  study  compares  the efﬁcacy  of two  recent  oral  ectoparasiticides  containing
isoxazolines  (NexGard®, containing  afoxolaner  and  administered  at a monthly  regimen,
and  BravectoTM containing  ﬂuralaner  and  administered  at a tri-monthly  regimen)  against
Rhipicephalus  sanguineus  sensu  lato  and  Dermacentor  reticulatus  ticks  on  dogs.
24  dogs  were  randomly  allocated  to untreated  control,  NexGard® treated,  and BravectoTM
treated  groups.  The  treatments  were  administered  on  Days 0, 28  and  56  for  afoxolaner  and
on  Day  0  for ﬂuralaner.  Tick infestations  were  performed  weekly  with  50 unfed  adult  ticks
per each  species  on  each  dog  from  Days  30 to 84  (with  the  exception  of R. sanguineus  on
Day  63).  Ticks  were  counted  at 24  h  post-infestation.
The  dogs  from  both  treated  groups  had  statistically  signiﬁcantly  (p  < 0.05)  less  R.  sang-
uineus  and  D. reticulatus  ticks  compared  to the  untreated  dogs  on  all  assessment  days.
Percent  efﬁcacy  against  R.  sanguineus  ranged  from  86.4%  to  99.5%  at 24  h  post-infestation
for  NexGard® and  from  65.7%  to 100%  for BravectoTM.  Statistically  signiﬁcantly  (p < 0.05)
less  R.  sanguineus  ticks  were  recorded  for NexGard® treated  dogs  compared  to BravectoTMtreated  dogs  on  Day  78. Percent  efﬁcacy  against  D. reticulatus  ranged  from  85.2%  to  99.6%
at 24 h  post-infestation  for NexGard® and  from  63.4%  to 99.1%  for BravectoTM. Statistically
signiﬁcantly  (p  <  0.05)  less  D. reticulatus  ticks  were  recorded  for NexGard® treated  dogs
compared  to BravectoTM treated  dogs  on  Days  71,  78  and 85.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB
1. Introduction
Ticks of the genus Dermacentor and Rhipicephalus are
of the most important vectors of severe canine diseases
(Chomel, 2011; Halos et al., 2013; Otranto et al., 2009).
The geographic distribution of both Rhipicephalus sanguin-
eus sensu lato and Dermacentor reticulatus tick species is
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expanding in Europe as a result of climate changes and
increasing movements of people travelling abroad with
their pets (Beugnet and Chalvet-Monfray, 2013; Dantas-
Torres et al., 2013). According to the standard determined
by pharmaceutical regulation worldwide, an anti-tick
product for dogs should provide a minimal activity of 90%
acaricidal efﬁcacy, characterized by a reduction in tick
counts 48 h after treatment and subsequent re-infestation
(Beugnet and Franc, 2012; EMEA, 2000; Halos et al., 2012;
Marchiondo et al., 2013). Recently, oral systemic ﬂea
and tick control formulations have been developed. Both
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foxolaner and ﬂuralaner are new insecticide-acaricide
olecules from the isoxazoline family that act on the insect
-aminobutyric acid receptor (GABA) and glutamate recep-
ors, resulting in excess neuronal stimulation and death
f the arthropod (Gassel et al., 2014; Lahm et al., 2013;
hoop et al., 2014). Afoxolaner is the active ingredient of
exGard® (Shoop et al., 2014), and ﬂuralaner is the active
ngredient of BravectoTM (Rohdich et al., 2014). Due to
heir pharmacokinetic properties and the minimum dose
dministered, 2.5 mg/kg of afoxolaner and 25 mg/kg of ﬂu-
alaner, respectively, they provide long-lasting insecticidal
nd acaricidal activity against ﬂeas and ticks (Letendre
t al., 2014; Kilp et al., 2014). NexGard® administered to
ogs kills ticks within 48 h after infestation for 4 weeks
EMA, 2014a, b; Dumont et al., 2014; Kunkle et al., 2014),
nd BravectoTM kills ticks within 48 h after infestation
or 8–12 weeks, according to tick species (EMA, 2014a,b).
ecause of the systemic mode of action of the products,
icks must attach and start ingesting material before being
illed. It can be hypothesized that ticks could be killed
ooner than 48 h after infestation in relation to the plasma
oncentration of the actives (Halos et al., 2014). The aim
f this study was to provide a comparative assessment
f killing efﬁcacy at 24 h against ticks during a 12 weeks
eriod for a single BravectoTM administration or 3 succes-
ive monthly administrations of NexGard®, according to
heir respective labelling in Europe.
. Materials and methods
The study was a parallel group design, randomized, sin-
le centre, blinded, controlled, study conducted in respect
f the Good Clinical Practices as described in International
ooperation on Harmonisation of Technical Requirements
or Registration of Veterinary Medicinal Products (VICH)
uideline GL9 (EMEA, 2000). It included three groups
f 8 dogs each: untreated dogs, NexGard® treated, and
ravectoTM treated.
The 24 dogs included were males and females of mixed
reeds, older than 6 months, with no restriction related to
air length, and weighing between 12 and 27.7 kg. They
ere clinically healthy, and they had not been treated
ith a long acting topical or systemic acaricide/insecticide
uring the 12 weeks preceding Day 0. The dogs were indi-
idually housed in cages.
Treatments were administered in accordance with the
uropean registration labels of NexGard® and BravectoTM
n Days 0, and again on Days 28 and 56 for NexGard®. The
ogs were fed immediately after administration according
o BravectoTM labelling.
Laboratory-bred strains of R. sanguineus sensu lato
strain originally collected in France and laboratory bred)
nd D. reticulatus (strain originally collected in France and
aboratory bred) were used for the infestations. The adult
icks were unfed, at least 3 months old and had a balanced
ex ratio (50% female/50% male). Each dog was artiﬁcially
nfested with 50 ticks per species (sex ratio 50/50) on each
nfestation day (Days 28, 35, 42, 49, 56, 63, 70, 77 and 84).
n Days 28 and 56, NexGard® treatment was applied at the
ime of tick challenge. Ticks were directly deposited on the
id-line of the dogs.ology 209 (2015) 142–145 143
Tick counting was  as close as possible to the speciﬁed
target time of 24 h ± 2. Ticks were assessed as attached or
free, dead or alive, and they were removed from the dogs
48 h after each infestation.
Efﬁcacy against ticks was  calculated for the treated
groups at each assessment day in accordance to WAAVP
guidelines, using the Abbott’s formula (Marchiondo et al.,
2013).
Efﬁcacy(%) = 100 × Mc − Mt
Mc
where Mc = arithmetic mean of live (attached of free) ticks
on the negative control group (group 1) and Mt = arithmetic
mean of live (attached of free) ticks on the Treatment-
administration groups (groups 2 or 3).
The groups were compared by a one-way ANOVA with
an administration effect on the untransformed live tick
counts.
3. Results
The arithmetic mean tick count for the negative con-
trol group ranged from 19.5 to 39.8 for Dermacentor and
from 26.6 to 40.1 for Rhipicephalus,  indicating viable tick
challenges on all assessment days (Table 1). The treated
groups had statistically signiﬁcantly (p < 0.05) less D. retic-
ulatus and R. sanguineus ticks compared to the untreated
control group on all assessments days. Statistically signif-
icantly (p < 0.05) less D. reticulatus ticks were recorded for
NexGard® treated dogs compared to BravectoTM treated
dogs at 24 h post-infestation on Days 71, 78 and 85. The dif-
ference was  signiﬁcant on Day 78 for R. sanguineus (Table 1).
No adverse events related to any of the treatments were
observed.
4. Discussion
Isoxazolines represent a new class of ectoparasiticides
acting systemically after oral administration (Shoop et al.,
2014; Gassel et al., 2014). Duration of effect is linked to
the dose of active administered, the peak plasma levels
achieved after ingestion, protein binding, and the drug’s
terminal plasma half-life of 12–15 days for ﬂuralaner for-
mulation (Kilp et al., 2014); and 15.5 (±7.8) days for
afoxolaner formulation (Letendre et al., 2014). The ﬁrst
tick infestations were conducted on Day 28 based on the
hypothesis that the ﬂuralaner concentration would be still
high enough to provide good efﬁcacy at 24 h counts. This
was conﬁrmed by the 98.7% and 100% of observed efﬁcacies
at Day 29 on Dermacentor and Rhipicephalus,  respectively.
Thereafter, the ﬂuralaner efﬁcacy observed at 24 h sig-
niﬁcantly decreased during the 3rd month. In contrast the
monthly administration of afoxolaner provided constant
efﬁcacy against both species of ticks even when evaluated
at 24 h after challenge. It indicates that tick death may be
linked to the duration of exposure to the actives. A longer
exposure is needed when the plasma concentration of the
acaricidal compound is lower, leading to a slower speed
of kill. The present study demonstrates that a monthly
administration of afoxolaner offers a more homogeneous
and constant protection compared to a single treatment
144 F. Beugnet et al. / Veterinary Parasitology 209 (2015) 142–145
Table 1
Efﬁcacy against Dermacentor reticulatus and Rhipicephalus sanguineus sensu lato ticks observed at 24 h (arithmetic means).
Days of infestation Dermacentor reticulatus
Arithmetic mean of tick counts at 24 h
Rhipicephalus sanguineus sensu lato















Day 28 19.5 0.1* (99.4) 0.3* (98.7) 26.6 0.1* (99.5) 0.0* (100.0)
Day  35 39.8 0.4* (99.1) 0.4* (99.1) 40.1 0.8* (98.1) 0.5* (98.8)
Day  42 34.1 2.0* (94.1) 2.1* (93.8) 35.8 1.0* (97.2) 1.5* (95.8)
Day  49 30.3 1.4* (95.5) 0.9* (97.1) 33.6 2.1* (93.7) 1.9* (94.4)
Day  56 32.4 0.1* (99.6) 2.9* (91.1) 36.1 0.9* (97.6) 2.8* (92.4)
Day  63 37.1 0.4* (99.0) 7.3* (80.5) NA NA NA
Day  70 34.0 1.4*1 (96.0) 8.4*1 (75.4) 34.5 2.8* (92.0) 8.6* (75.0)
Day  77 33.6 1.9*1 (94.4) 11.9*1 (64.7) 33.5 2.1*1 (93.7) 11.5*1 (65.7)
Day  84 30.4 4.5*1 (85.2) 11.1*1 (63.4) 34.1 4.6* (86.4%) 9.6* (71.8%)
*p-Value from control <0.0001. p-Value: one-way ANOVA with a treatment effect.
1(bold): statistically signiﬁcantly differences (p < 0.05) were recorded between treated groups.
hed of fr%Efﬁcacy = 100 × (Mc − Mt)/Mc , where Mc = arithmetic mean of live (attac
(attached of free) ticks on the Treatment-administration groups.
with ﬂuralaner. Similar conclusions were recently obtained
in regard to ﬂea efﬁcacy (Beugnet et al., 2015). Assessing
anti-tick efﬁcacy at earlier time-points than the classi-
cal 48 h provides an idea of the potential to decrease the
risk of pathogen transmission, even if these molecules act
by systemic way. It has been recently demonstrated with
afoxolaner preventing the transmission of Babesia canis by
infected ticks (Beugnet et al., 2014).
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